Bafna Pharmaceuticals Limited BAFNAPHshare price and chart
Bafna Pharmaceuticals closed at ₹479.50 on 19 November 2026, up 1.93% on the day. The 52-week range is ₹94.77 to ₹501.65.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on BAFNAPH
Real prices, every charge counted. Pick one or write your own.Bafna Pharmaceuticals, a 31-year-old company, develops, makes and exports finished medicines and is a contract research and manufacturing partner. It has 336 formulations across antibiotics, anti-infectives, supplements, cardiovascular, diabetes, nervous system and oncology, exported to more than 20 countries.
Pharmaceuticals & Biotechnology
Generic formulations, contract research and manufacturing
Regulated and emerging export markets, pharmaceutical partners
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 19 NovReturns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026What the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 11 Nov 2026), sales rose 34.4% from a year earlier to ₹47.7 cr and profit rose 119.1% to ₹6.8 cr.
- Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
- No promoter shares were pledged at the end of September 2026.
- Promoter holding fell 13.3 points over 8 quarters (88.30% to 75.00%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Share price reaction to resultsWhat the share price did around each recent quarterly result.
Over the last 20 results, the share rose on 10 and fell on 10, and moved by 3% or more on 12.
Q2 FY27: results filed 11 Nov 2026. The share went from its close on 9 Nov 2026 to its close on 12 Nov 2026 +4.03%.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 5 years this compounded at +29.9% a year. The last twelve months were up +181.2%. Price only, before dividends.
Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorRevenue and profit, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹7.4 as profit. Other income added ₹3.2.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearCash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash fell by ₹1 Cr, after ₹25 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | 35.5% | 32.3% | -4.3% | 3.2% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 13.3% | 7.3% | 7.7% | 10.6% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | 9.8% | 4.8% | 2.9% | 7.4% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | 15.4% | 9.5% | 5.0% | 12.3% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | 14.2% | 9.6% | 6.3% | 11.9% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.31x | 0.30x | 0.33x | 0.39x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | 6.8x | 4.2x | 2.6x | 4.0x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.0 | -4.9 | +3.0 | +22.6 | -1.6 | +62.7 | +22.5 | +15.7 | +22.1 | +20.6 | +7.1 | · | +218.1% 11m |
| 2025 | +1.4 | -8.0 | +1.6 | +6.8 | -6.1 | +12.1 | +4.0 | +18.8 | +69.7 | -18.5 | +5.3 | -0.4 | +91.0% |
| 2024 | +6.5 | -10.7 | -10.5 | +21.0 | -5.1 | -16.1 | +13.9 | -6.2 | +5.3 | -7.6 | +1.8 | -1.4 | -14.3% |
| 2023 | -2.2 | -2.6 | -14.5 | -1.3 | +32.9 | -0.8 | -14.7 | +12.5 | -18.5 | +3.2 | +1.7 | +4.9 | -8.7% |
| 2022 | -8.2 | -13.6 | +4.7 | +7.0 | -17.6 | +3.0 | -5.3 | +5.4 | -11.2 | -0.8 | +0.5 | -0.8 | -33.9% |
| 2021 | -27.3 | -0.2 | +10.8 | -4.8 | +2.8 | +4.7 | +9.3 | -13.5 | -3.5 | -5.2 | -3.8 | +30.2 | -10.7% |
| 2020 | · | · | · | +53.0 | +0.0 | +10.1 | +0.0 | +4.9 | +77.7 | +176.4 | +16.0 | +27.6 | +1184.6% 9m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2026-08-06 | M7 GLOBAL FUND PCC-AERION · bulk | SELL | 6,66,000 | ₹284.55 | ₹18.95 Cr |
| 2026-08-06 | CULLINAN OPPRTS FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1 · bulk | BUY | 6,66,000 | ₹284.55 | ₹18.95 Cr |
- Board outcomeOutcome of Board Meeting11 Nov 2026
Bafna Pharmaceuticals Limited has submitted to the Exchange, the Outcome of the Board Meeting held on 11/11/2026 along with the Unaudited Financial Results and Limited Review Report issued by the Statutory Auditors, for the Quarter and Half Year ended September 30, 2026.
- Board outcomeOutcome of Board Meeting11 Aug 2026
Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 11/08/2026 along with the unaudited financial results for the quarter ended June 30, 2026.
- Board outcomeOutcome of Board Meeting29 May 2026
Bafna Pharmaceuticals Limited has submitted to the Exchange, the Audited financial results for the Quarter and Year ended March 31, 2026.
- Board outcomeOutcome of Board Meeting11 Feb 2026
Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on February 11, 2026 along with the Unaudited financial results and Limited Review Report for the Quarter and Nine Months ended December 31, 2025.
- Board outcomeOutcome of Board Meeting11 Nov 2025
Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on November 11, 2025 along with the Unaudited financial results and Limited Review Report for the Quarter and Half Year ended September 30, 2025.
- Board outcomeOutcome of Board Meeting12 Aug 2025
Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 12/08/2025 along with the unaudited financial results for the quarter ended June 30, 2025.
- Board outcomeOutcome of Board Meeting26 May 2025
Bafna Pharmaceuticals Limited has submitted to the Exchange, Outcome of the Board Meeting held on 26/05/2025 along with the Audited Financial Results for the Quarter and Year ended March 31, 2025.
- Integrated Filing- Financial6 Feb 2025
Integrated Filing (Financial) for the Quarter and Nine Months ended December 31, 204
- Financial Result Updates6 Feb 2025
Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test BAFNAPH. “Buy BAFNAPH when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free